Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but n...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	EJNMMI research Ročník 9; číslo 1; s. 1 - 7
Hlavní autori:	Schollhammer, Romain, De Clermont Gallerande, Henri, Yacoub, Mokrane, Quintyn Ranty, Marie-Laure, Barthe, Nicole, Vimont, Delphine, Hindié, Elif, Fernandez, Philippe, Morgat, Clément
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin/Heidelberg Springer Berlin Heidelberg 03.06.2019 Springer Nature B.V SpringerOpen
Predmet:	Antigens Binding Cancer surgery Cardiac Imaging GRP-R Histology Imaging Inhibitors Medicine Medicine & Public Health Metastasis Nuclear Medicine Oncology Original Research Orthopedics Prostate cancer PSMA Radiology Tracers Tumors GRP-R Prostate cancer PSMA
ISSN:	2191-219X, 2191-219X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer. Procedures We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111 In-PSMA-617 and the radiolabeled GRP-R antagonist 111 In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks). Results Binding of 111 In-PSMA-617 was high whatever the metastatic risk ( p = 0.665), Gleason score ( p = 0.555), or PSA value ( p = 0.404) while 111 In-RM2 exhibited a significantly higher binding in the low metastatic risk group ( p = 0.046), in the low PSA value group ( p = 0.001), and in samples with Gleason 6 score ( p = 0.006). Conclusion PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.
AbstractList	Abstract Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer. Procedures We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks). Results Binding of 111In-PSMA-617 was high whatever the metastatic risk (p = 0.665), Gleason score (p = 0.555), or PSA value (p = 0.404) while 111In-RM2 exhibited a significantly higher binding in the low metastatic risk group (p = 0.046), in the low PSA value group (p = 0.001), and in samples with Gleason 6 score (p = 0.006). Conclusion PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed. Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer. Procedures We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111 In-PSMA-617 and the radiolabeled GRP-R antagonist 111 In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks). Results Binding of 111 In-PSMA-617 was high whatever the metastatic risk ( p = 0.665), Gleason score ( p = 0.555), or PSA value ( p = 0.404) while 111 In-RM2 exhibited a significantly higher binding in the low metastatic risk group ( p = 0.046), in the low PSA value group ( p = 0.001), and in samples with Gleason 6 score ( p = 0.006). Conclusion PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed. Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer.PURPOSEProstate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer.We retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D'Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks).PROCEDURESWe retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D'Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks).Binding of 111In-PSMA-617 was high whatever the metastatic risk (p = 0.665), Gleason score (p = 0.555), or PSA value (p = 0.404) while 111In-RM2 exhibited a significantly higher binding in the low metastatic risk group (p = 0.046), in the low PSA value group (p = 0.001), and in samples with Gleason 6 score (p = 0.006).RESULTSBinding of 111In-PSMA-617 was high whatever the metastatic risk (p = 0.665), Gleason score (p = 0.555), or PSA value (p = 0.404) while 111In-RM2 exhibited a significantly higher binding in the low metastatic risk group (p = 0.046), in the low PSA value group (p = 0.001), and in samples with Gleason 6 score (p = 0.006).PSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.CONCLUSIONPSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed. PurposeProstate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but never compared. We aimed to gather comparative preclinical data of the role of PSMA and GRP-R targeting in prostate cancer.ProceduresWe retrospectively studied 20 frozen prostatectomy samples with various metastatic risks of the D’Amico classification. Tissue samples were investigated by tissular microimaging using the radiolabeled PSMA inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2. Bindings of the two radiopharmaceuticals were compared to histology and clinico-biological data (Gleason score, PSA values, metastatic risks).ResultsBinding of 111In-PSMA-617 was high whatever the metastatic risk (p = 0.665), Gleason score (p = 0.555), or PSA value (p = 0.404) while 111In-RM2 exhibited a significantly higher binding in the low metastatic risk group (p = 0.046), in the low PSA value group (p = 0.001), and in samples with Gleason 6 score (p = 0.006).ConclusionPSMA and GRP-R based imaging might have complementary performances for the initial characterization of prostatic tumors. Prospective clinical studies comparing the two tracers in this setting are needed.
ArticleNumber	52
Author	Vimont, Delphine Fernandez, Philippe Hindié, Elif Barthe, Nicole Morgat, Clément Schollhammer, Romain Yacoub, Mokrane Quintyn Ranty, Marie-Laure De Clermont Gallerande, Henri
Author_xml	– sequence: 1 givenname: Romain surname: Schollhammer fullname: Schollhammer, Romain email: romain.scho@gmail.com organization: Nuclear Medicine Department, University Hospital of Bordeaux, University of Bordeaux, INCIA, UMR5287, CNRS, INCIA, UMR5287 – sequence: 2 givenname: Henri surname: De Clermont Gallerande fullname: De Clermont Gallerande, Henri organization: Nuclear Medicine Department, University Hospital of Bordeaux – sequence: 3 givenname: Mokrane surname: Yacoub fullname: Yacoub, Mokrane organization: Department of Pathology, University Hospital of Bordeaux – sequence: 4 givenname: Marie-Laure surname: Quintyn Ranty fullname: Quintyn Ranty, Marie-Laure organization: Department of Pathology, University Hospital of Toulouse – sequence: 5 givenname: Nicole surname: Barthe fullname: Barthe, Nicole organization: BioTis, Inserm U1026 – sequence: 6 givenname: Delphine surname: Vimont fullname: Vimont, Delphine organization: University of Bordeaux, INCIA, UMR5287, CNRS, INCIA, UMR5287 – sequence: 7 givenname: Elif surname: Hindié fullname: Hindié, Elif organization: Nuclear Medicine Department, University Hospital of Bordeaux, University of Bordeaux, INCIA, UMR5287, CNRS, INCIA, UMR5287 – sequence: 8 givenname: Philippe surname: Fernandez fullname: Fernandez, Philippe organization: Nuclear Medicine Department, University Hospital of Bordeaux, University of Bordeaux, INCIA, UMR5287, CNRS, INCIA, UMR5287 – sequence: 9 givenname: Clément surname: Morgat fullname: Morgat, Clément organization: Nuclear Medicine Department, University Hospital of Bordeaux, University of Bordeaux, INCIA, UMR5287, CNRS, INCIA, UMR5287
BookMark	eNp9Ustu1DAUjVARLaUfwC4SGzYB3_iVbJCqEZSRWlENILGzHOdmxqOMPdgeJL6CX8ZpBkGLwAtf6_qccx86T4sT5x0WxXMgrwAa8ToC5ZxUBNqKcJCVeFSc1dBCla8vJ3-8T4uLGLckHw68pc2T4pQCCGC8PSt-LPxur4ON3pV-KNMGy6B760fd4Yh9efvx5rKybmM7m3woAWDpqrukAFlq1_9NuVrdVqv8lfTaOxvTkbS6qUvryn2wOx2-5-hj0glLo53BUEa9248YnxWPBz1GvDjG8-Lzu7efFu-r6w9Xy8XldWUYo6kagDSMEiF6wjj0XLNWmIY2dcekIDWThhMjDLSIBDSXOQrZQMsgwxgSel4sZ93e6606NqW8tuou4cNa6ZCsGVE1HRXNgJJQ1Eww3fQtgYZ2BkDqbhBZ682stT90O-wNuhT0eE_0_o-zG7X235TgTEgBWeDlUSD4rweMSe1sNDiO2qE_RFXXlBOZa7YZ-uIBdOsPweVVTShGsxqrM0rOKJO3HAMOyti8bOun-nZUQNTkITV7SGUPqclDapoFHjB_jfE_Tj1zYsa6NYbfPf2b9BNfTNaH
CitedBy_id	crossref_primary_10_1002_cmdc_202400843 crossref_primary_10_3389_fonc_2023_1199432 crossref_primary_10_1007_s00330_022_08982_2 crossref_primary_10_1186_s13550_025_01232_8 crossref_primary_10_1007_s11307_023_01851_4 crossref_primary_10_3390_cancers15082345 crossref_primary_10_1007_s00259_023_06142_2 crossref_primary_10_3390_ph14020167 crossref_primary_10_1007_s13246_024_01510_0 crossref_primary_10_1016_j_cpet_2022_07_006 crossref_primary_10_1186_s13550_020_0598_2 crossref_primary_10_3389_fonc_2023_1072510 crossref_primary_10_1186_s41181_020_00115_8 crossref_primary_10_3390_cancers16203490 crossref_primary_10_3390_molecules27217216 crossref_primary_10_1097_MOU_0000000000000794 crossref_primary_10_2174_0929867327666200312114902 crossref_primary_10_1186_s40658_020_00301_2 crossref_primary_10_3390_cancers13246255 crossref_primary_10_3390_pharmaceutics13081160 crossref_primary_10_1016_j_mednuc_2023_07_008 crossref_primary_10_1016_j_nano_2025_102829
Cites_doi	10.2967/jnumed.117.195172 10.1001/jama.280.11.969 10.2967/jnumed.115.169748 10.1007/s00259-018-4037-9 10.3322/caac.21387 10.1007/s00259-017-3631-6 10.1371/journal.pone.0210905 10.1002/pros.22743 10.1159/000447164 10.2967/jnumed.114.142000 10.1158/1078-0432.CCR-12-3490 10.1371/journal.pone.0145755 10.1016/S1569-9056(15)60217-2 10.2967/jnumed.115.169599 10.2967/jnumed.117.204032 10.2967/jnumed.117.191031 10.2967/jnumed.116.178889 10.1038/nrurol.2013.42 10.1016/j.euo.2018.08.011 10.1007/s00259-013-2525-5 10.1016/j.eururo.2017.03.009 10.1021/bc200279b 10.1002/pros.21434 10.2967/jnumed.114.147413 10.2967/jnumed.117.198929 10.2967/jnumed.118.209387 10.1007/s11548-015-1233-y 10.1021/jm5012066
ContentType	Journal Article
Copyright	The Author(s). 2019 EJNMMI Research is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s). 2019 – notice: EJNMMI Research is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION 3V. 7X7 7XB 8AO 8FE 8FG 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BENPR BGLVJ CCPQU DWQXO FYUFA GHDGH HCIFZ K9. M0S P5Z P62 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s13550-019-0517-6
DatabaseName	SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials - QC ProQuest Central Technology collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Proquest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef Publicly Available Content Database Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) Advanced Technologies & Aerospace Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2191-219X
EndPage	7
ExternalDocumentID	oai_doaj_org_article_8b368fe703ea464a8d90183bc117abf6 PMC6546761 10_1186_s13550_019_0517_6
GrantInformation_xml	– fundername: La ligue contre le Cancer de Gironde grantid: 2016 – fundername: ; grantid: 2016
GroupedDBID	-A0 0R~ 3V. 40G 53G 5VS 7X7 8AO 8FE 8FG 8FI 8FJ AAFWJ AAJSJ AAKKN ABDBF ABEEZ ABUWG ACACY ACGFS ACIHN ACUHS ACULB ADBBV ADINQ AEAQA AENEX AFGXO AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS ARAPS BAPOH BCNDV BENPR BFQNJ BGLVJ BPHCQ BVXVI C24 C6C CCPQU EBLON EBS EJD FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE HZ~ IAO IHR ITC KQ8 M48 M~E OK1 P62 PGMZT PIMPY PQQKQ PROAC RBZ RNS RPM RSV SMD SOJ U2A UKHRP AASML AAYXX CITATION 7XB 8FK AZQEC DWQXO K9. PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c443t-f10843066d0451d5a496c8382b4760247c50c6c19ee01a579ee67819416c84e03
IEDL.DBID	C24
ISICitedReferencesCount	29
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000470138800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2191-219X
IngestDate	Fri Oct 03 12:41:22 EDT 2025 Tue Nov 04 02:03:16 EST 2025 Fri Sep 05 12:09:14 EDT 2025 Thu Oct 09 21:50:33 EDT 2025 Sat Nov 29 05:31:28 EST 2025 Tue Nov 18 20:55:44 EST 2025 Fri Feb 21 02:37:22 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	GRP-R Prostate cancer PSMA
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c443t-f10843066d0451d5a496c8382b4760247c50c6c19ee01a579ee67819416c84e03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://link.springer.com/10.1186/s13550-019-0517-6
PMID	31161459
PQID	2234361342
PQPubID	2034773
PageCount	7
ParticipantIDs	doaj_primary_oai_doaj_org_article_8b368fe703ea464a8d90183bc117abf6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6546761 proquest_miscellaneous_2235071839 proquest_journals_2234361342 crossref_citationtrail_10_1186_s13550_019_0517_6 crossref_primary_10_1186_s13550_019_0517_6 springer_journals_10_1186_s13550_019_0517_6
PublicationCentury	2000
PublicationDate	2019-06-03
PublicationDateYYYYMMDD	2019-06-03
PublicationDate_xml	– month: 06 year: 2019 text: 2019-06-03 day: 03
PublicationDecade	2010
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Heidelberg
PublicationTitle	EJNMMI research
PublicationTitleAbbrev	EJNMMI Res
PublicationYear	2019
Publisher	Springer Berlin Heidelberg Springer Nature B.V SpringerOpen
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V – name: SpringerOpen
References	Borkowski, DOEHR, HULTSCH (CR17) 2012; 53 Storz, Shah, Zettinig (CR28) 2015; 14 Mansi, Fleischmann, Mäcke, Reubi (CR7) 2013; 10 Spick, Herrmann, Czernin (CR20) 2016; 57 Siegel, Miller, Jemal (CR1) 2017; 67 Parent, Schuster (CR21) 2018; 59 Calais, Kishan, Cao (CR30) 2018; 59 Kahkonen, Jambor, Kemppainen (CR8) 2013; 19 Morgat, Schollhammer, Macgrogan (CR19) 2019; 14 Zhang, Niu, Fan (CR10) 2018; 59 D’Amico, Whittington, Malkowicz (CR13) 1998; 280 Touijer, Michaud, Alvarez (CR24) 2018; 2 Schwarzenboeck, Rauscher, Bluemel (CR5) 2017; 58 Moschini, Carroll, Eggener (CR26) 2017; 72 Eder, Schäfer, Bauder-Wüst (CR3) 2012; 23 Nitsch, Hakenberg, Heuschkel (CR22) 2016; 57 Körner, Waser, Rehmann, Reubi (CR12) 2014; 74 Mansi, Abiraj, Wang (CR15) 2015; 58 Morgat, Mishra, Varshney (CR4) 2014; 55 Reubi, Kvols, Waser (CR14) 1990; 50 Woythal, Arsenic, Kempkensteffen (CR25) 2018; 59 Uprimny, Kroiss, Decristoforo (CR6) 2017; 44 Afshar-Oromieh, Zechmann, Malcher (CR2) 2014; 41 Gourni, Canovas, Goncalves (CR16) 2015; 10 Porcaro, Siracusano, de Luyk (CR27) 2017; 10 Beer, Montani, Gerhardt (CR11) 2012; 72 Liu, Liu, Zhang (CR23) 2018; 45 Benešová, Schäfer, Bauder-Wüst (CR18) 2015; 56 Nock, Kaloudi, Lymperis (CR9) 2017; 58 Zettinig, Shah, Hennersperger (CR29) 2015; 10 AB Porcaro (517_CR27) 2017; 10 BA Nock (517_CR9) 2017; 58 AV D’Amico (517_CR13) 1998; 280 A Afshar-Oromieh (517_CR2) 2014; 41 R Mansi (517_CR15) 2015; 58 C Liu (517_CR23) 2018; 45 S Nitsch (517_CR22) 2016; 57 C Morgat (517_CR19) 2019; 14 M Moschini (517_CR26) 2017; 72 J Zhang (517_CR10) 2018; 59 C Morgat (517_CR4) 2014; 55 E Gourni (517_CR16) 2015; 10 C Spick (517_CR20) 2016; 57 N Woythal (517_CR25) 2018; 59 M Beer (517_CR11) 2012; 72 E Kahkonen (517_CR8) 2013; 19 EE Parent (517_CR21) 2018; 59 S Borkowski (517_CR17) 2012; 53 C Uprimny (517_CR6) 2017; 44 JC Reubi (517_CR14) 1990; 50 J Calais (517_CR30) 2018; 59 KA Touijer (517_CR24) 2018; 2 SM Schwarzenboeck (517_CR5) 2017; 58 M Körner (517_CR12) 2014; 74 M Benešová (517_CR18) 2015; 56 M Eder (517_CR3) 2012; 23 RL Siegel (517_CR1) 2017; 67 E Storz (517_CR28) 2015; 14 O Zettinig (517_CR29) 2015; 10 R Mansi (517_CR7) 2013; 10
References_xml	– volume: 59 start-page: 238 year: 2018 end-page: 243 ident: CR25 article-title: Immunohistochemical validation of PSMA expression measured by Ga-PSMA PET/CT in primary prostate cancer publication-title: J Nucl Med doi: 10.2967/jnumed.117.195172 – volume: 280 start-page: 969 year: 1998 end-page: 974 ident: CR13 article-title: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer publication-title: JAMA doi: 10.1001/jama.280.11.969 – volume: 57 start-page: 38S year: 2016 end-page: 42S ident: CR22 article-title: Evaluation of prostate cancer with C- and F-choline PET/CT: diagnosis and initial staging publication-title: J Nucl Med doi: 10.2967/jnumed.115.169748 – volume: 45 start-page: 1852 year: 2018 end-page: 1861 ident: CR23 article-title: Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-018-4037-9 – volume: 53 start-page: 177 issue: supplement 1 year: 2012 ident: CR17 article-title: Preclinical validation of the Ga-68- bombesin antagonist BAY 86-7548 for a phase I study in prostate cancer patients publication-title: J Nucl Med – volume: 67 start-page: 7 year: 2017 end-page: 30 ident: CR1 article-title: Cancer statistics, 2017 publication-title: CA Cancer J Clin doi: 10.3322/caac.21387 – volume: 44 start-page: 941 year: 2017 end-page: 949 ident: CR6 article-title: Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-017-3631-6 – volume: 14 start-page: e0210905 year: 2019 ident: CR19 article-title: Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist Ga-RM2 and F-FDG in breast cancer samples publication-title: PLoS One doi: 10.1371/journal.pone.0210905 – volume: 74 start-page: 217 year: 2014 end-page: 224 ident: CR12 article-title: Early over-expression of GRP receptors in prostatic carcinogenesis publication-title: Prostate doi: 10.1002/pros.22743 – volume: 10 start-page: 118 year: 2017 end-page: 125 ident: CR27 article-title: Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system publication-title: Curr Urol doi: 10.1159/000447164 – volume: 55 start-page: 1650 year: 2014 end-page: 1657 ident: CR4 article-title: Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors publication-title: J Nucl Med doi: 10.2967/jnumed.114.142000 – volume: 19 start-page: 5434 year: 2013 end-page: 5443 ident: CR8 article-title: In vivo imaging of prostate cancer using [ Ga]-labeled bombesin analog BAY86-7548 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3490 – volume: 50 start-page: 5969 year: 1990 end-page: 5977 ident: CR14 article-title: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas publication-title: Cancer Res – volume: 10 start-page: e0145755 year: 2015 ident: CR16 article-title: (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors publication-title: PLoS One doi: 10.1371/journal.pone.0145755 – volume: 14 start-page: e217 year: 2015 ident: CR28 article-title: PSMA-PET/MRI-guided transrectal fusion biopsy for the detection of prostate cancer publication-title: Eur Urol Suppl doi: 10.1016/S1569-9056(15)60217-2 – volume: 57 start-page: 30S year: 2016 end-page: 37S ident: CR20 article-title: Evaluation of prostate cancer with C-acetate PET/CT publication-title: J Nucl Med doi: 10.2967/jnumed.115.169599 – volume: 59 start-page: 733 year: 2018 end-page: 739 ident: CR21 article-title: Update on F-Fluciclovine PET for prostate cancer imaging publication-title: J Nucl Med doi: 10.2967/jnumed.117.204032 – volume: 58 start-page: 1545 year: 2017 end-page: 1552 ident: CR5 article-title: PSMA ligands for PET imaging of prostate cancer publication-title: J Nucl Med doi: 10.2967/jnumed.117.191031 – volume: 58 start-page: 75 year: 2017 end-page: 80 ident: CR9 article-title: Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results publication-title: J Nucl Med doi: 10.2967/jnumed.116.178889 – volume: 10 start-page: 235 year: 2013 end-page: 244 ident: CR7 article-title: Targeting GRPR in urological cancers--from basic research to clinical application publication-title: Nat Rev Urol doi: 10.1038/nrurol.2013.42 – volume: 2 start-page: 166 issue: 2 year: 2018 end-page: 173 ident: CR24 article-title: Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2018.08.011 – volume: 41 start-page: 11 year: 2014 end-page: 20 ident: CR2 article-title: Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2525-5 – volume: 72 start-page: 238 year: 2017 end-page: 249 ident: CR26 article-title: Low-risk prostate cancer: identification, management, and outcomes publication-title: Eur Urol doi: 10.1016/j.eururo.2017.03.009 – volume: 23 start-page: 688 year: 2012 end-page: 697 ident: CR3 article-title: Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging publication-title: Bioconjug Chem doi: 10.1021/bc200279b – volume: 72 start-page: 318 year: 2012 end-page: 325 ident: CR11 article-title: Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates publication-title: Prostate doi: 10.1002/pros.21434 – volume: 56 start-page: 914 year: 2015 end-page: 920 ident: CR18 article-title: Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer publication-title: J Nucl Med doi: 10.2967/jnumed.114.147413 – volume: 59 start-page: 922 year: 2018 end-page: 928 ident: CR10 article-title: PET using a GRPR antagonist Ga-RM26 in healthy volunteers and prostate cancer patients publication-title: J Nucl Med doi: 10.2967/jnumed.117.198929 – volume: 59 start-page: 1714 year: 2018 end-page: 1721 ident: CR30 article-title: Potential impact of Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning publication-title: J Nucl Med doi: 10.2967/jnumed.118.209387 – volume: 10 start-page: 1997 year: 2015 end-page: 2007 ident: CR29 article-title: Multimodal image-guided prostate fusion biopsy based on automatic deformable registration publication-title: Int J Comput Assist Radiol Surg doi: 10.1007/s11548-015-1233-y – volume: 58 start-page: 682 year: 2015 end-page: 691 ident: CR15 article-title: Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors publication-title: J Med Chem doi: 10.1021/jm5012066 – volume: 58 start-page: 682 year: 2015 ident: 517_CR15 publication-title: J Med Chem doi: 10.1021/jm5012066 – volume: 2 start-page: 166 issue: 2 year: 2018 ident: 517_CR24 publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2018.08.011 – volume: 72 start-page: 318 year: 2012 ident: 517_CR11 publication-title: Prostate doi: 10.1002/pros.21434 – volume: 280 start-page: 969 year: 1998 ident: 517_CR13 publication-title: JAMA doi: 10.1001/jama.280.11.969 – volume: 19 start-page: 5434 year: 2013 ident: 517_CR8 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3490 – volume: 14 start-page: e0210905 year: 2019 ident: 517_CR19 publication-title: PLoS One doi: 10.1371/journal.pone.0210905 – volume: 41 start-page: 11 year: 2014 ident: 517_CR2 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2525-5 – volume: 59 start-page: 733 year: 2018 ident: 517_CR21 publication-title: J Nucl Med doi: 10.2967/jnumed.117.204032 – volume: 55 start-page: 1650 year: 2014 ident: 517_CR4 publication-title: J Nucl Med doi: 10.2967/jnumed.114.142000 – volume: 10 start-page: 1997 year: 2015 ident: 517_CR29 publication-title: Int J Comput Assist Radiol Surg doi: 10.1007/s11548-015-1233-y – volume: 56 start-page: 914 year: 2015 ident: 517_CR18 publication-title: J Nucl Med doi: 10.2967/jnumed.114.147413 – volume: 74 start-page: 217 year: 2014 ident: 517_CR12 publication-title: Prostate doi: 10.1002/pros.22743 – volume: 57 start-page: 30S year: 2016 ident: 517_CR20 publication-title: J Nucl Med doi: 10.2967/jnumed.115.169599 – volume: 10 start-page: e0145755 year: 2015 ident: 517_CR16 publication-title: PLoS One doi: 10.1371/journal.pone.0145755 – volume: 45 start-page: 1852 year: 2018 ident: 517_CR23 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-018-4037-9 – volume: 10 start-page: 118 year: 2017 ident: 517_CR27 publication-title: Curr Urol doi: 10.1159/000447164 – volume: 14 start-page: e217 year: 2015 ident: 517_CR28 publication-title: Eur Urol Suppl doi: 10.1016/S1569-9056(15)60217-2 – volume: 57 start-page: 38S year: 2016 ident: 517_CR22 publication-title: J Nucl Med doi: 10.2967/jnumed.115.169748 – volume: 58 start-page: 75 year: 2017 ident: 517_CR9 publication-title: J Nucl Med doi: 10.2967/jnumed.116.178889 – volume: 44 start-page: 941 year: 2017 ident: 517_CR6 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-017-3631-6 – volume: 59 start-page: 1714 year: 2018 ident: 517_CR30 publication-title: J Nucl Med doi: 10.2967/jnumed.118.209387 – volume: 59 start-page: 922 year: 2018 ident: 517_CR10 publication-title: J Nucl Med doi: 10.2967/jnumed.117.198929 – volume: 67 start-page: 7 year: 2017 ident: 517_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21387 – volume: 72 start-page: 238 year: 2017 ident: 517_CR26 publication-title: Eur Urol doi: 10.1016/j.eururo.2017.03.009 – volume: 53 start-page: 177 issue: supplement 1 year: 2012 ident: 517_CR17 publication-title: J Nucl Med – volume: 59 start-page: 238 year: 2018 ident: 517_CR25 publication-title: J Nucl Med doi: 10.2967/jnumed.117.195172 – volume: 23 start-page: 688 year: 2012 ident: 517_CR3 publication-title: Bioconjug Chem doi: 10.1021/bc200279b – volume: 10 start-page: 235 year: 2013 ident: 517_CR7 publication-title: Nat Rev Urol doi: 10.1038/nrurol.2013.42 – volume: 50 start-page: 5969 year: 1990 ident: 517_CR14 publication-title: Cancer Res – volume: 58 start-page: 1545 year: 2017 ident: 517_CR5 publication-title: J Nucl Med doi: 10.2967/jnumed.117.191031
SSID	ssj0000515938
Score	2.2838976
Snippet	Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with... PurposeProstate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with... Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled... Abstract Purpose Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted...
SourceID	doaj pubmedcentral proquest crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher
StartPage	1
SubjectTerms	Antigens Binding Cancer surgery Cardiac Imaging GRP-R Histology Imaging Inhibitors Medicine Medicine & Public Health Metastasis Nuclear Medicine Oncology Original Research Orthopedics Prostate cancer PSMA Radiology Tracers Tumors
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yiPgifmL1lAg-KeGaJpsmj-fhqeAey6pwbyFf5QqSlXbPf8N_2UmaXa8n6otPLfmgTWam8xsm_Q1CL40T1gmniHK0IxxcMtwZQxruJaWi7lTIVUs-tmdn8vxcra6U-kpnwiZ64GnjjqRlQnYBFDMYLriRHjyYZNZR2hrbZbJtQD1XgqnC6r1QTJY0JpXiaKTgWdMZLEUSLRURM0eU-fpnIPP6EclredLsfk7vojsFN-Lj6X3voRsh3ke3liUz_gD9ONkXFMSbDgOsw4PxPQSuFhyLx6tPy2PSx4veggkPGL49HyLJjQAusIn-9ynv1iuyhq6Ut0r8umXSetngPuJvE00FXDf5pyTskv4MeDSJb3h8iL6cvv188p6UYgvEcc62pKO15BA_CJ8YZ_zCcCWcZLKxvBXgyFu3qEGoVIVQU7No4Qp-jioAdE7yULNH6CBuYniMsDE8MGFrH1L42DETrGs861hCk7xlFap3O69dYSJPBTG-6hyRSKEnYWkQlk7C0qJCr_ZTyvr-NvhNEud-YGLQzg2gV7rolf6XXlXocKcMupj1qAFLcQYAiDcVerHvBoNMWRYTw-Yyj0kYG4BnhdqZEs1eaN4T-4tM7Z1-LWsFrdDrnbr9evgf1_vkf6z3KbrdZOMQpGaH6GA7XIZn6Kb7vu3H4Xm2rp_yWCVa priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVgixAXvhGBgozECWQ1jr2Oc0Jt1QISu1otIPVmOY7TRkJJm2z7N_jLzHi9W6WIXjgliu3E1oxnnj3OG0LeW6dKp1zBCsdrJsElw521LJOV5lyldeFD1pJv-XyuT06KRdxwG-Kxyo1NDIa66hzuke-BG5MCfI_MPp1fMMwahdHVmELjLtlBpjI5ITsHR_PFcrvLghlMCqFjOJNrtTdw8LB4FqtgSE_F1MghBd7-Edi8eVTyRrw0uKHjR_87gMfkYQSgdH-tMU_IHd8-JfdnMcT-jPw-3GYmpF1NAR_S3lYNrIBL8FAVXXyf7bOmPWtKsAU9BSP2tWXhIaAUatvq7yaflwu2hCIMgCFRb2y0nGW0aen5mu8Crl34u4k6VMSeDhaJi4fn5Ofx0Y_DLyxmbWBOSrFiNU-1hIWIqpC6pppaWSinhc5KmStABLmbpqAdvPA-5XaawxUcJgiPQzXpU_GCTNqu9S8JtVZ6ocq08rgOrYX1pcsqUQuEpTIXCUk3ojMuUppjZo1fJixttDJraRuQtkFpG5WQD9smcXy3VT5AfdhWRCru8KDrT02c2UaXQunag-X0VippdQUQS4vScZ7bsoaX7G70wUT7MJhrZUjIu20xzGwM19jWd5ehDoJ1QLAJyUdaOOrQuKRtzgJHOP6jliuekI8bfb3--D_H--r2rr4mD7IwbxRLxS6ZrPpL_4bcc1erZujfxqn3B8kJNIQ priority: 102 providerName: ProQuest
Title	Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
URI	https://link.springer.com/article/10.1186/s13550-019-0517-6 https://www.proquest.com/docview/2234361342 https://www.proquest.com/docview/2235071839 https://pubmed.ncbi.nlm.nih.gov/PMC6546761 https://doaj.org/article/8b368fe703ea464a8d90183bc117abf6
Volume	9
WOSCitedRecordID	wos000470138800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 2191-219X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000515938 issn: 2191-219X databaseCode: RBZ dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2191-219X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000515938 issn: 2191-219X databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2191-219X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000515938 issn: 2191-219X databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 2191-219X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000515938 issn: 2191-219X databaseCode: C24 dateStart: 20111201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dj5QwFG3cXWN88duIrpOa-KRppLSU8rg7mdVNZEJGTUZfSClll8TABmb30b_gX_a2U8awfiT6UghtGSjn9p7ObU8Reqm0KLXQKUk1rQkHlwxnSpGIV5JSEdapcbuWvE-WS7lep7lfxz2Ms93HkKTrqZ1ZS_FmoOAa7SSqlFhdKSL20EFMZWphPfdLHLygd5wy6SOYv6058UFOqn_CL6_PjrwWInWe5-Tufz3zPXTHE018tEXGfXTDtA_QrcyH0h-i7_PdDoS4qzHwQNyrqoGRbgmeqML5h-yINO15U4LN9xg6q9OWuIvARrBqq1-rvF3lZAVZNtBlBXl9pVUW4abFF1tdCzh2bhUT1hZwPR6UFSgeHqFPJ4uP83fE785ANOdsQ2oaSg4DDlFZiZoqVjwVWjIZlTwR4PkTHYeAApoaE1IVJ3AEx0hTYIBachOyx2i_7VrzBGGluGGiDCtjx5s1U6bUUcVqZuknT1iAwvF7FdpLl9sdNL4WbggjRbFt6AIaurANXYgAvdpV8e_3t8LHFgS7glZy213o-rPCW3AhSyZkbaCHNIoLrmQFVEqyUlOaqLKGmxyOECp8PzAUQL44A8bEowC92GWDBduwjGpNd-nKWFIOTDVAyQR6kwea5rTNudMCt2vREkED9HoE4M8f_-P7Pv2n0s_Q7cghWJCQHaL9TX9pnqOb-mrTDP0M7SXrxKVyhg6OF8t8NXMGOXN_b0CafVtAmsdfID8_zfLPPwACxTB5
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwED-NDgEv_EcrDDASvICsxbHrOA8IjcFYtbaqypDGk3Ech0WakpF0ID4F34TPyDlNOnWIve2Bp1SxnTjp7-53l7PvAJ4bKxMrbUxjyzIqkJLxlzE0FKliTAZZ7JqqJaNoMlGHh_F0DX53e2H8sspOJzaKOi2t_0a-hTQmOHKPCN-cfKO-apSPrnYlNBaw2Hc_f6DLVr8evsP_90UY7r4_2NmjbVUBaoXgc5qxQAk0lGXqU6ukAyNiaRVXYSIiiYwV2UGAs2excwEzgwiPqNDR12fYTbiA43WvwLpAsKserE-H4-nn5VcdXzEl5qoNnzIlt2qGjO7XfsXUp8OicoUAmzoBK8bt-aWZ5-KzDe3t3vrfXthtuNka2GR7IRF3YM0Vd-HauF1CcA9-7SwrL5IyI2j_ksqkOXr4CTJwSqYfx9s0L47yBHVdRVBJDwvanEQrjJgi_XvIh9mUzrDJB_h8IuJ20GwckrwgJ4t8Hngsm91bxHpBq0htfGLm-j58upTX8QB6RVm4DSDGCMdlEqTO-9kZNy6xYcoz7s1uEfE-BB1UtG1TtvvKIce6cd2U1At0aUSX9ujSsg8vl0Pa57uo81uPv2VHn2q8OVFWX3WrubRKuFSZQ2ZwRkhhVIompOKJZSwySYYX2ezwp1v9V-sz8PXh2bIZNZcPR5nCladNH--MoIXeh2gF9SsTWm0p8qMmB7rfgxdJ1odXnXyc3fyfz_vw4qk-het7B-ORHg0n-4_gRtjIrKQB34TevDp1j-Gq_T7P6-pJK_YEvly24PwBBAmM5Q
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELZKQRUX_hGBAkaCC8jaOPY6zgGh0rKwane1WkCquATHcWgklJRkC-IpeB-ejhlvstUW0VsPnBLFdhInM_PNeMYzhDw1VmVW2YQllhdMAiTDmTEskrnmXIVF4nzVkoN4OtWHh8lsg_zu98JgWGUvE72gzmuLa-QDgDEpAHtkNCi6sIjZ3ujV8TeGFaTQ09qX01iSyL77-QPMt_bleA_-9bMoGr35sPuOdRUGmJVSLFjBQy1BaVY5plnJh0Ymymqho0zGCtArtsMQZsIT50JuhjEcQbiD3c-hm3ShgPteIpdjsDGRu2bDT6v1HaydkgjdOVK5VoOWA7ZjFFjCMDEWU2tQ6CsGrKm5Z4M0z3hqPQCOrv_Pn-4Gudap3XRnySc3yYarbpGtSRdYcJv82l3VY6R1QUErpo3JS7D7M8DlnM7eT3ZYWR2VGUjAhoLoHlfMXwTdjJoq_3vI2_mMzaEJ3X6YnrgbNJ9EtKzo8TLLBxxrv6eLWmS_hrYG0zW3d8jHC_kcd8lmVVfuHqHGSCdUFuYOre9CGJfZKBeFQGVcxiIgYU82qe0SuWM9ka-pN-i0SpeUlgKlpUhpqQrI89WQbn7ndX6NtLjqiAnI_YW6-ZJ28izVmVC6cIAXzkgljc5BsdQis5zHJivgJts9LaadVGzTU0IMyJNVM8gzdFKZytUnvg-aKKC3ByRe44C1F1pvqcojnxkdd-bFigfkRc8rpw__53zvn_-qj8kWcEt6MJ7uPyBXI8--ioVim2wumhP3kFyx3xdl2zzy_E_J54vmmj8MwZRI
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+radiolabeled+PSMA-inhibitor+111In-PSMA-617+and+the+radiolabeled+GRP-R+antagonist+111In-RM2+in+primary+prostate+cancer+samples&rft.jtitle=EJNMMI+research&rft.au=Schollhammer%2C+Romain&rft.au=De+Clermont+Gallerande%2C+Henri&rft.au=Yacoub%2C+Mokrane&rft.au=Quintyn+Ranty%2C+Marie-Laure&rft.date=2019-06-03&rft.pub=Springer+Berlin+Heidelberg&rft.eissn=2191-219X&rft.volume=9&rft_id=info:doi/10.1186%2Fs13550-019-0517-6&rft_id=info%3Apmid%2F31161459&rft.externalDocID=PMC6546761
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2191-219X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2191-219X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2191-219X&client=summon